ArticleJournal of cancer research and clinical oncology2022

Targeting abundant survivin expression in liposarcoma: subtype dependent therapy responses to YM155 treatment.

Christian Vay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.